GSK, Endo to settle testosterone drug lawsuits

Feb 27, 2018

GlaxoSmithKline and Endo Pharmaceuticals have agreed to settle lawsuits that accused both companies of obscuring the risks of a testosterone-boosting drug marketed to middle-aged men, according to court filings.

The settlement is set to resolve more than 1,300 suits filed by men who blame the Endo-manufactured drug, which was promoted by GSK, for causing blood clots.

U.S. District Judge Matthew Kennelly, who is overseeing more than 6,000 testosterone cases, is putting on hold all litigation against Endo and GSK while the the settlement details are finalized.

Read the Bloomberg Report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments